TCE2 Stock Overview
A biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Celldex Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.80 |
| 52 Week High | US$47.80 |
| 52 Week Low | US$21.80 |
| Beta | 1.59 |
| 11 Month Change | -6.77% |
| 3 Month Change | -21.52% |
| 1 Year Change | -1.59% |
| 33 Year Change | -30.57% |
| 5 Year Change | 1,080.95% |
| Change since IPO | -55.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| TCE2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.5% | -0.7% | -0.02% |
| 1Y | -1.6% | -17.2% | 8.2% |
Return vs Industry: TCE2 exceeded the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: TCE2 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| TCE2 volatility | |
|---|---|
| TCE2 Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TCE2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: TCE2's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 160 | Anthony Marucci | www.celldex.com |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity.
Celldex Therapeutics, Inc. Fundamentals Summary
| TCE2 fundamental statistics | |
|---|---|
| Market cap | €1.67b |
| Earnings (TTM) | -€147.96m |
| Revenue (TTM) | €9.58m |
179.7x
P/S Ratio-11.6x
P/E RatioIs TCE2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TCE2 income statement (TTM) | |
|---|---|
| Revenue | US$9.98m |
| Cost of Revenue | US$147.04m |
| Gross Profit | -US$137.06m |
| Other Expenses | US$17.02m |
| Earnings | -US$154.08m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.32 |
| Gross Margin | -1,373.91% |
| Net Profit Margin | -1,544.48% |
| Debt/Equity Ratio | 0% |
How did TCE2 perform over the long term?
See historical performance and comparison